摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

尼可待因 | 3688-66-2

中文名称
尼可待因
中文别名
烟酸可待因酯
英文名称
4,5α-epoxy-3-methoxy-17-methyl-6α-nicotinoyloxy-morphin-7-ene
英文别名
nicocodine;[(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] pyridine-3-carboxylate
尼可待因化学式
CAS
3688-66-2
化学式
C24H24N2O4
mdl
——
分子量
404.466
InChiKey
RYBGRHAWFUVMST-MJFIPZRTSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    30
  • 可旋转键数:
    4
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    60.9
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    烟酸吡啶氯化亚砜 作用下, 以 氯仿 为溶剂, 反应 22.0h, 生成 尼可待因
    参考文献:
    名称:
    Hosztafi; Kohegyi; Simon, Arzneimittel-Forschung/Drug Research, 1993, vol. 43, # 11, p. 1200 - 1203
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] HETEROARYL AMIDE ANALOGUES<br/>[FR] ANALOGUES D'HÉTÉROARYLAMIDES
    申请人:NEUROGEN CORP
    公开号:WO2009023623A1
    公开(公告)日:2009-02-19
    Compounds, pharmaceutical compositions, and methods of use are disclosed for heteroaryl amide analogues of formula Ia and/or Ib: . In certain embodiments, the heteroaryl amide analogues are agonists and/or ligands of dopamine receptors and may be useful, inter alia, for the treatment of a condition responsive to P2X7 receptor modulation, for example, pain, inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder or an immune system disorder.
    公开了公式Ia和/或Ib的杂环酰胺类似物的化合物、药物组合物和使用方法。在某些实施例中,这些杂环酰胺类似物是多巴胺受体的激动剂和/或配体,可能有助于治疗对P2X7受体调节敏感的疾病,例如疼痛、炎症、神经系统或神经退行性疾病、心血管疾病、眼部疾病或免疫系统疾病。
  • [EN] COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF<br/>[FR] COMPOSITIONS COMPRENANT DES PROMÉDICAMENTS OPIACÉS CLIVABLES PAR ENZYME ET LEURS INHIBITEURS
    申请人:PHARMACOFORE INC
    公开号:WO2011133149A1
    公开(公告)日:2011-10-27
    The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.
    本公开提供了一种药物组合物及其使用方法,其中所述药物组合物包含一种前药,该前药能够提供通过酶控释放的药物,以及一种酶抑制剂,该酶抑制剂与介导从该前药酶控释放药物的酶相互作用,以减弱前药的酶裂解。本公开还提供了包含酶抑制剂和含酶可裂解基团的前药的药物组合物,所述酶可裂解基团在裂解时有助于药物的释放。
  • [EN] COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF<br/>[FR] COMPOSITIONS COMPRENANT DES PROMÉDICAMENTS CLIVABLES PAR ENZYME DE PRINCIPES ACTIFS ET LEURS INHIBITEURS
    申请人:PHARMACOFORE INC
    公开号:WO2011133150A1
    公开(公告)日:2011-10-27
    The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.
    本公开提供了一种药物组合物及其使用方法,其中所述药物组合物包含一种前药,该前药能够提供通过酶控释放的药物,以及一种酶抑制剂,该酶抑制剂与介导药物从该前药通过酶控释放的酶相互作用,以减弱前药的酶切。本公开还提供了一种包含酶抑制剂和前药的药物组合物,所述前药包含一个酶可切割的部分,切割后可促进药物的释放。
  • COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF
    申请人:Jenkins Thomas E.
    公开号:US20110262355A1
    公开(公告)日:2011-10-27
    Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.
    提供的药物组合物及其使用方法,其中药物组合物包括一种阿片类药物的前药,该前药提供酶控释放的阿片类药物,以及一种酶抑制剂,该酶抑制剂与介导阿片类药物前药酶控释放的酶相互作用,以减弱对阿片类药物前药的酶切。
  • METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE
    申请人:Waterville Valley Technologies, Inc.
    公开号:US20160326182A1
    公开(公告)日:2016-11-10
    Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.
    提供了耐滥用的阿片类化合物、药物输送系统、含有阿片类药物与化学基团共价结合的制药组合物。还提供了将活性成分输送给受试者的方法以及预防阿片类药物滥用的方法。
查看更多